Drug Product Development, Bristol Myers Squibb, NJ, USA.
Analytical Sciences and Technology, Bristol Myers Squibb, NJ, USA.
Int J Pharm. 2024 Dec 5;666:124785. doi: 10.1016/j.ijpharm.2024.124785. Epub 2024 Sep 30.
The challenges of developing good quality low dose minitablets was assessed by systematically studying the effects of ibuprofen (IBU, a model compound) particle sizes (6-58 µm D) and concentrations (0.1-3 %w/w), roller compaction forces (3-7 kN/cm), and the minitablet sizes (1.2, 1.5 and 2 mm diameter). A novel compression approach, where all three minitablet sizes were simultaneously produced in a single compression run was used. Roller compacted ribbons, granules, minitablets were characterized for physico-mechanical properties and minitablets were also characterized for stratified content uniformity and weight uniformity. The results showed that roll force was the more dominant factor to ribbon solid fraction or tensile strength and granule size enlargement. Minitablets obtained from the granules had good weight uniformity; all but one batch met the <Ph. Eur. 2.9.5 > criteria. The precise control of tooling lengths across the various sizes was found profoundly important for achieving expected weights, solid fraction, and tensile strength of the simultaneously produced minitablets. The roller compaction process considerably improved the CU variability of the minitablets as compared to the direct compression process. Smaller particle size and higher concentration of IBU, increased roller compaction force, and larger minitablet size improved the potency and content uniformity; however, only the minitablet size was a statistically significant factor in this study. As a product strategic design criterion, a threshold of 25 minitablets in a dosage unit would ensure robust downstream filling and weight verification operations as well as dose accuracy and uniformity (would pass <USP 905> stage 1 criteria). This study results demonstrated feasibility of the novel simultaneous compression approach and the roller compaction process in developing good quality minitablets.
采用系统研究布洛芬(IBU,模型化合物)粒径(6-58μm D)和浓度(0.1-3%w/w)、压辊压力(3-7kN/cm)以及片剂直径(1.2、1.5 和 2mm)的方法,评估了开发高质量低剂量迷你片剂的挑战。采用了一种新颖的压缩方法,即在单次压缩运行中同时生产所有三种迷你片剂尺寸。对压辊压实的条带、颗粒、迷你片剂进行了物理机械性能的表征,并对迷你片剂进行了分层含量均匀性和重量均匀性的表征。结果表明,压辊力是影响条带固体分数或拉伸强度和颗粒尺寸增大的更主导因素。从颗粒中获得的迷你片剂具有良好的重量均匀性;除一批外,所有批次均符合<Ph. Eur. 2.9.5>标准。发现通过各种尺寸的模具长度的精确控制对于实现预期的重量、固体分数和同时生产的迷你片剂的拉伸强度非常重要。与直接压缩工艺相比,辊压工艺大大提高了迷你片剂的含量均匀度变异性。较小的 IBU 粒径和较高的浓度、增加的压辊压力以及较大的迷你片剂尺寸提高了效力和含量均匀性;然而,在本研究中,只有迷你片剂尺寸是一个统计学上显著的因素。作为产品战略设计标准,一个剂量单位 25 粒迷你片剂的阈值将确保稳健的下游填充和重量验证操作以及剂量准确性和均匀性(将通过<USP 905>第 1 阶段标准)。这项研究结果证明了新颖的同时压缩方法和辊压工艺在开发高质量迷你片剂方面的可行性。